Specification
| Target | PD-L1 |
| Reactivities | Human |
| Biosimilar | Atebio |
| Isotype | Human IgG1 (N297A)-Kappa |
| Property | Antibody |
| Alternative | MPDL 3280A; MPDL3280A;B7-H; B7H1; B7-H1; B7H1PDCD1L1; CD274 antigenMGC142294; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDCD1LG1MGC142296; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1; hPD-L1;PD-L1; hPD-L1;PD-L1 |
| Recommend Isotype | Anti-HEL Human IgG1 (N297A)-Kappa Isotype control |
| Formulation Buffer | PBS, pH 7.4,Contains no stabilizers or preservatives |
| Recommend Buffer | PBS, pH 7.4,Contains no stabilizers or preservatives. |
| Endotoxin | <0.1EU/mg Determined by LAL gel clotting assay |
| Purity | >95% Determined by SDS-PAGE |
| Sterility | 0.2 μM filtered |
| Expression Host | CHO |
| Purification method | IEC |
| Storage | The product should be stored at the original stock concentration at 4°C. Avoid freeze-thaw cycles. |
| Note | Due to the variability in applications, investigators should consult application references to estimate the appropriate dose or concentration. This dose or concentration can then be further optimized through experimental methods such as dose-response or titration experiments |
Background
QC Data
| Note | Please contact us for QC Data |
| Product Image (Reference Only) |  |